Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
IMV-102 in Relapse multiple myeloma: NCT07493135 Clinical Landscape Report 2026
18 September 2026
NCT07493135 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Renal Pelvis and Ureter Urothelial Carcinoma: NCT07492628 Clinical Landscape Report 2026
18 September 2026
NCT07492628 clinical landscape for Renal Pelvis and Ureter Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
CD19/CD20/FCGR trispecific antibody(Hinge Bio) in Lupus Nephritis: NCT07491900 Clinical Landscape Report 2026
18 September 2026
NCT07491900 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine) in Sjogren's Syndrome: NCT07490041 Clinical Landscape Report 2026
18 September 2026
NCT07490041 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chondroitin Sulfate Sodium in Cystitis: NCT07495072 Clinical Landscape Report 2026
18 September 2026
NCT07495072 clinical landscape for Cystitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revumenib in Acute Myeloid Leukemia: NCT07498465 Clinical Landscape Report 2026
18 September 2026
NCT07498465 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Methotrexate Sodium in Psoriasis vulgaris: CTRI/2026/03/107054 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/03/107054 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Xeligekimab in Pustulosis of Palms and Soles: NCT07503652 Clinical Landscape Report 2026
18 September 2026
NCT07503652 clinical landscape for Pustulosis of Palms and Soles: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Uveal Melanoma: NCT07501117 Clinical Landscape Report 2026
18 September 2026
NCT07501117 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Human IL12/15-PDL1B Herpes simplex type I oncolytic virus(Vero cell)(Virogin) in Non-Muscle Invasive Bladder Neoplasms: NCT07505615 Clinical Landscape Report 2026
18 September 2026
NCT07505615 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ivosidenib in Acute myeloid leukaemia with 11q23 abnormality: NCT07507760 Clinical Landscape Report 2026
18 September 2026
NCT07507760 clinical landscape for Acute myeloid leukaemia with 11q23 abnormality: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
Equecabtagene Autoleucel in Relapse multiple myeloma: NCT07510100 Clinical Landscape Report 2026
18 September 2026
NCT07510100 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.